CRYSTALLINE FORM OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1 H-PYRAZOL-3-YLAMINO)-6-ETHYL-1 -METHYL-1,6-DIHYRDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE-7-CARBOXAMIDE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS
Crystalline form, Form N-2, of N, Ndicyclopropyl-4-(l,5-dimethyl-1 Hpyrazol-3-ylamino)-6-ethyl-l-methyl-l,6-dihydroimidazo[4,5- d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising Form N-2 of Compound I as well as a method of using the Form N-2 of Compound I in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.Linvention concerne une forme cristalline, la forme N-2, de N,Ndicyclopropyl-4-(1,5-diméthyl-1Hpyrazol-3-ylamino)-6-éthyl-1-méthyl-1,6-dihydro-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (Composé I). Linvention concerne également une composition pharmaceutique et une forme posologique orale comprenant la forme N-2 du composé I, ainsi quune méthode dutilisation de la forme N-2 du composé I dans le traitement de troubles myéloprolifératifs, qui comprennent la polyglobulie primitive, la thrombocytémie et la myélofibrose primaire.
